# Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer

> **NCT02136836** · — · UNKNOWN · sponsor: **Yonsei University** · enrollment: 860 (estimated)

## Conditions studied

- Stomach Neoplasms

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02136836
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-05
- **Primary completion:** 2015-03
- **Final completion:** —
- **Target enrollment:** 860 (ESTIMATED)
- **Last updated:** 2014-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02136836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02136836, "Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02136836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*